Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007371
Filing Date
2025-05-12
Accepted
2025-05-12 16:05:28
Documents
54
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acxp-20250331x10q.htm   iXBRL 10-Q 1214028
2 EX-31.1 acxp-20250331xex31d1.htm EX-31.1 12535
3 EX-31.2 acxp-20250331xex31d2.htm EX-31.2 12540
4 EX-32.1 acxp-20250331xex32d1.htm EX-32.1 5408
5 EX-32.2 acxp-20250331xex32d2.htm EX-32.2 5446
  Complete submission text file 0001558370-25-007371.txt   4452233

Data Files

Seq Description Document Type Size
6 EX-101.SCH acxp-20250331.xsd EX-101.SCH 33467
7 EX-101.CAL acxp-20250331_cal.xml EX-101.CAL 17053
8 EX-101.DEF acxp-20250331_def.xml EX-101.DEF 135205
9 EX-101.LAB acxp-20250331_lab.xml EX-101.LAB 291318
10 EX-101.PRE acxp-20250331_pre.xml EX-101.PRE 228833
57 EXTRACTED XBRL INSTANCE DOCUMENT acxp-20250331x10q_htm.xml XML 463524
Mailing Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305
Business Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305 917-533-1469
Acurx Pharmaceuticals, Inc. (Filer) CIK: 0001736243 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40536 | Film No.: 25934713
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)